Canaccord lowered the firm’s price target on Repligen (RGEN) to $145 from $165 and keeps a Hold rating on the shares. The firm updated its model ahaead of Q1 results and they believe the shares could be attractive with continued momentum or additional material share price pullback. They are optimistic regarding the tools and diagnostics sector from the company-specific and macro perspectives.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls
- Repligen opens new Training & Innovation Center in Netherlands
- Repligen initiated with a Buy at Rothschild & Co Redburn
- Repligen price target lowered to $145 from $175 at Barclays
- Repligen price target lowered to $140 from $170 at Evercore ISI